STERIS (NYSE:STE) Upgraded by Wall Street Zen to “Strong-Buy” Rating

STERIS (NYSE:STE) was upgraded by investment analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings reissued a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, STERIS has an average rating of “Moderate Buy” and a consensus target price of $275.20.

STERIS Trading Down 3.4%

NYSE STE opened at $230.49 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.48 and a quick ratio of 1.75. The stock has a market capitalization of $22.60 billion, a P/E ratio of 32.15 and a beta of 1.05. The firm’s 50-day moving average is $254.37 and its two-hundred day moving average is $251.51. STERIS has a 12 month low of $204.90 and a 12 month high of $269.44.

STERIS (NYSE:STE) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. During the same quarter in the previous year, the firm earned $2.32 earnings per share. The company’s revenue for the quarter was up 9.2% compared to the same quarter last year. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, sell-side analysts anticipate that STERIS will post 9.08 earnings per share for the current year.

Insider Buying and Selling

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of the company’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $237.21, for a total transaction of $734,876.58. Following the sale, the director owned 705 shares in the company, valued at $167,233.05. This represents a 81.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.07% of the stock is owned by insiders.

Hedge Funds Weigh In On STERIS

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Trust Co. of Vermont increased its stake in shares of STERIS by 30.2% during the fourth quarter. Trust Co. of Vermont now owns 164 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 38 shares during the period. Bailard Inc. grew its holdings in STERIS by 3.5% during the 4th quarter. Bailard Inc. now owns 1,118 shares of the medical equipment provider’s stock worth $283,000 after acquiring an additional 38 shares in the last quarter. Magnolia Capital Advisors LLC increased its position in shares of STERIS by 1.2% in the 3rd quarter. Magnolia Capital Advisors LLC now owns 3,588 shares of the medical equipment provider’s stock valued at $888,000 after purchasing an additional 41 shares during the last quarter. Colonial Trust Co SC raised its holdings in shares of STERIS by 0.3% in the 3rd quarter. Colonial Trust Co SC now owns 12,329 shares of the medical equipment provider’s stock valued at $3,051,000 after purchasing an additional 42 shares in the last quarter. Finally, Allworth Financial LP raised its holdings in shares of STERIS by 7.3% in the 2nd quarter. Allworth Financial LP now owns 661 shares of the medical equipment provider’s stock valued at $159,000 after purchasing an additional 45 shares in the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.